Priyanka Belawat
Director/Board Member chez Neurelis, Inc.
Provenance du réseau au premier degré de Priyanka Belawat
| Entité | Type d'entité | Industrie | |
|---|---|---|---|
HBM Partners AG
 HBM Partners AG Investment ManagersFinance HBM Partners AG (HBM-P) was established in 2001 as an independent provider of investment advisory services with headquarters in Zug, Switzerland. HBM-P's field of expertise comprises global human medicine, biotechnology, medical technology and related sectors. The firm primarily advises HBM BioVentures AG and HBM BioCapital via their Cayman Islands-based, wholly-owned subsidiary, HBM Partners (Cayman) Ltd., which acts as the investment manager for the HBM funds. They rely on the services of an external consultant to analyze investment opportunities in the US.
24
| Private Company | Investment Managers | 24 |
| Public Company | Biotechnology | 15 | |
iTeos Therapeutics SA
 iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium.
12
| Subsidiary | Pharmaceuticals: Major | 12 |
| Public Company | Biotechnology | 11 | |
Neurelis, Inc.
 Neurelis, Inc. Pharmaceuticals: MajorHealth Technology Neurelis, Inc. operates as a specialty pharmaceutical company. It is organized to license, develop and commercialize product candidates for the treatment of central nervous system disorders with a focus on the acute treatment of epilepsy and anxiety episodes. The company was founded by Craig C. Chambliss and David F. Hale in 2007 and is headquartered in San Diego, CA.
10
| Holding Company | Pharmaceuticals: Major | 10 |
Mahzi Therapeutics, Inc.
 Mahzi Therapeutics, Inc. BiotechnologyHealth Technology Mahzi Therapeutics is a private biotechnology company that focuses on genetic therapies for rare genetic neurodevelopmental disorders. The company was founded by Yael Weiss and is based in San Mateo, CA. The company unites patient and family groups, academic researchers, diagnostic companies, other industry members, and its internal team of experts to develop therapies for patients with these serious diseases. Mahzi's team is experienced in all aspects of biopharmaceutical research, development, and manufacturing and is driven to make a difference in the lives of patients with rare genetic diseases. Yael Weiss has been the CEO since incorporation.
6
| Holding Company | Biotechnology | 6 |
AdrenoMed AG
 AdrenoMed AG Pharmaceuticals: MajorHealth Technology AdrenoMed AG develops a drug to decrease mortality in severe sepsis. The company was founded by Bernd Wegener, Gerald Heinz Möller and Andreas Bergmann in 2009 and is headquartered in Berlin, Germany.
5
| Holding Company | Pharmaceuticals: Major | 5 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Priyanka Belawat via son réseau personnel
| Société | Secteur | Personnes liées | Poste principal |
|---|---|---|---|
| BIOGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal Sales & Marketing | |
| QUESTCOR PHARMACEUTICALS INC | Pharmaceuticals: Major | Chief Operating Officer Sales & Marketing | |
UBS Securities LLC
 UBS Securities LLC Investment Banks/BrokersFinance UBS Securities LLC is an investment bank and registered broker/dealer headquartered in New York City. The firm was founded in 1998 as UBS Warburg LLC. They are a subsidiary of UBS Americas Holding LLC, ultimately held by UBS Group AG (SWX: UBSG, NYSE: UBS) in Switzerland. UBS Securities is a primary dealer in US Government securities and provides a full range of investment banking services which includes corporate finance, mergers and acquisitions, capital markets, trading and sales, fixed-income, equity research, private banking, underwriting and prime brokerage operations. The firm also provides advisory services and access to capital markets for corporate, institutional, intermediary and alternative asset management clients. | Investment Banks/Brokers | Analyst-Equity Corporate Officer/Principal | |
| IDENIX PHARMACEUTICALS INC | Pharmaceuticals: Major | Director/Board Member Investor Relations Contact | |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Medical Specialties | Corporate Officer/Principal Corporate Officer/Principal | |
| CHEMOCENTRYX, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Tensys Medical, Inc.
 Tensys Medical, Inc. Medical/Nursing ServicesHealth Services Tensys Medical, Inc. develops blood pressure monitoring systems. The firm provides patient safety by designing, and manufacturing continuous, non-invasive hemodynamic monitoring systems. The company was founded in 1995 and is headquartered in San Diego, CA. | Medical/Nursing Services | Director/Board Member Chairman | |
Elan Pharmaceuticals, LLC
 Elan Pharmaceuticals, LLC Pharmaceuticals: MajorHealth Technology Elan Pharmaceuticals LLC develops and manufactures pharmaceutical products. It specializes in treatment of neurological and autoimmune diseases. The firm's drugs are used in the treatment of for Alzheimer's, Parkinson's, and rheumatoid arthritis diseases. The company is headquartered in South San Francisco, CA. | Pharmaceuticals: Major | Sales & Marketing Corporate Officer/Principal Human Resources Officer Corporate Officer/Principal | |
| ZOGENIX, INC. | Pharmaceuticals: Major | Founder Director of Finance/CFO Sales & Marketing | |
| SUTRO BIOPHARMA, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| EVOKE PHARMA, INC. | Pharmaceuticals: Major | Founder Director/Board Member | |
| ULTRAGENYX PHARMACEUTICAL INC. | Pharmaceuticals: Major | Director of Finance/CFO Director/Board Member | |
MPM BioImpact, Inc
 MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Investment Managers | Founder Private Equity Investor Private Equity Investor | |
| GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
Duke University
 Duke University Other Consumer ServicesConsumer Services Duke University is an academic university that offers undergraduate, graduate and professional programs. It also has publications and research services. The university was founded in 1838 and is headquartered in Durham, NC. | College/University | Undergraduate Degree Doctorate Degree | |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Corporate Officer/Principal Masters Business Admin | |
Novo Holdings AS (Denmark)
 Novo Holdings AS (Denmark) MiscellaneousMiscellaneous Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark. | Miscellaneous | Corporate Officer/Principal Corporate Officer/Principal | |
| College of the Holy Cross (Massachusetts) | College/University | Undergraduate Degree Undergraduate Degree | |
| HBM HEALTHCARE INVESTMENTS AG | Investment Managers | Founder Chief Executive Officer Director of Finance/CFO | |
| MIRATI THERAPEUTICS | Biotechnology | Director/Board Member Director/Board Member | |
ESBATech, a Novartis Co. GmbH
 ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
B·R·A·H·M·S GmbH
 B·R·A·H·M·S GmbH Miscellaneous Commercial ServicesCommercial Services B·R·A·H·M·S GmbH engages in the development and manufacture of novel diagnostic testing procedures. Its products include B·R·A·H·M·S PCT (Procalcitonin), MR-proADM (Mid-regional proadrenomedullin), Copeptin proAVP, Neopterin, and KRYPTOR Instruments. The company was founded in 1994 and is headquartered in Hennigsdorf, Germany. | Miscellaneous Commercial Services | Chairman Founder Founder Founder | |
| Swiss Federal Institute of Technology | College/University | Graduate Degree Doctorate Degree Doctorate Degree | |
Ogeda SA
 Ogeda SA Pharmaceuticals: MajorHealth Technology Ogeda SA discovers and develops small molecule drugs. It develops NK3 antagonists for the treatment of hormone-dependent pathologies in the field of Women's Health. The company was founded in 1994 and is headquartered in Gosselies, Spain. | Pharmaceuticals: Major | Corporate Officer/Principal Director/Board Member | |
| Vlerick Leuven Gent Management School | College/University | Masters Business Admin Masters Business Admin | |
Omnes Capital SAS /Venture/
 Omnes Capital SAS /Venture/ Investment ManagersFinance Omnes Capital SAS /Venture/ is a Venture Capital firm, a subsidiary of Omnes Capital SAS founded in 1999. Omnes Capital /Venture/ is headquartered in Paris. | Investment Managers | Private Equity Investor Private Equity Investor | |
Sanford Burnham Prebys Medical Discovery Institute
 Sanford Burnham Prebys Medical Discovery Institute Medical/Nursing ServicesHealth Services Sanford Burnham Prebys Medical Discovery Institute conducts and translates biological research programs. The firm offers tumor initiation and maintenance, cancer metabolism and signaling network, tumor microenvironment and cancer immunology, degenerative disease, development/aging/regeneration, immunity and pathogenesis, human genetic, cardiovascular metabolism, integrative metabolism, metabolism genomic control, bioinformatics and structural biology programs. The company was founded by William Fishman and Lillian Fishman in 1976 and is headquartered in La Jolla, CA. | Medical/Nursing Services | Director/Board Member Corporate Officer/Principal | |
| DEUTSCHE BIOTECH INNOVATIV AG | Financial Conglomerates | Chief Executive Officer Chief Operating Officer Founder | |
| VICORE PHARMA HOLDING AB | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| The University of Chicago Booth School of Business | College/University | Masters Business Admin Masters Business Admin | |
HBM Healthcare Investments (Cayman) Ltd.
 HBM Healthcare Investments (Cayman) Ltd. Hospital/Nursing ManagementHealth Services Part of HBM Partners AG, HBM Healthcare Investments (Cayman) Ltd. provides healthcare services. The private company is based in George Town, Cayman Islands. Andreas Wicki has been the CEO of the company since 2001. | Hospital/Nursing Management | Chief Executive Officer Director/Board Member | |
HBM Partners AG (Investment Management)
 HBM Partners AG (Investment Management) Investment ManagersFinance HBM Partners AG (Investment Management) (HBM-IM) is the asset management division of HBM Partners AG. The firm is headquartered in Zug and was founded in 2001. HBM-IM provides investment advisory services to private companies. They manage the fund HBM Healthcare Investments. | Investment Managers | Chief Executive Officer Portfolio Manager-Equities Analyst-Equity Portfolio Manager-Equities | |
| Harvard Business School | College/University | Masters Business Admin Masters Business Admin Masters Business Admin | |
Corvidia Therapeutics, Inc.
 Corvidia Therapeutics, Inc. BiotechnologyHealth Technology Corvidia Therapeutics, Inc. is a biotechnology company focusing on cardiovascular therapies. It develops treatments for atherosclerotic cardiovascular disease, inflammation in chronic kidney diseases, and high triglyceride-induced acute pancreatitis. The company was founded by Michael H. Davidson, Rahul Kakkar, Matt Devalaraja, and Ram Aiyar in 2015 and is headquartered in Waltham, MA. | Biotechnology | Director/Board Member Corporate Officer/Principal | |
Vitaeris, Inc.
 Vitaeris, Inc. BiotechnologyHealth Technology Vitaeris, Inc. develops new treatment options for chronic inflammatory diseases. The company was founded by Kevin Chow, Patrick A. Robinson and Noel F. Hall in 2016 and is headquartered in Vancouver, Canada. | Biotechnology | Director/Board Member Corporate Officer/Principal | |
Vivet Therapeutics SAS
 Vivet Therapeutics SAS BiotechnologyHealth Technology Vivet Therapeutics SAS develops novel gene therapy treatments for inherited metabolic diseases. The firm offers its services under the categorizers of Biopharma, Biotechnology and Health Care. The company was founded by Jean-Philippe Combal, Gloria Gonzalez-Aseguinolaza and Jens Kurth on July 26, 2016 and is headquartered in Paris, France. | Biotechnology | Director/Board Member Director/Board Member | |
| ALLOVIR, INC. | Biotechnology | Director/Board Member Chairman | |
| HARMONY BIOSCIENCES HOLDINGS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Harmony Biosciences LLC
 Harmony Biosciences LLC Pharmaceuticals: MajorHealth Technology Harmony Biosciences LLC operates as a biopharmaceutical company which develops therapies to help patients with unmet medical needs. It provides novel treatment options to patients with orphan and rare conditions, with an emphasis on central nervous system disorders. The company is headquartered in Plymouth Meeting, PA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
ElevateBio LLC
 ElevateBio LLC BiotechnologyHealth Technology ElevateBio LLC is a biotechnology holding company, which creates and operates a broad portfolio of cell and gene therapy companies. It builds single and multi-product companies by providing scientific founders with bench-to-bedside capabilities including scientists, manufacturing facilities, drug developers, and commercial expertise. The company was founded by David L. Hallal, Vikas Sinha, and Mitchell H. Finer and is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member Chief Executive Officer | |
Nextpoint Therapeutics, Inc.
 Nextpoint Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Nextpoint Therapeutics, Inc. is a biotech company based in Cambridge, MA. The company is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. The company's innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Nextpoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies. Detlev Biniszkiewicz has been the CEO of the company since 2018. | Miscellaneous Commercial Services | Chairman Director/Board Member | |
Hemab ApS
 Hemab ApS BiotechnologyHealth Technology Hemab ApS develops antibodies for the treatment of rare bleeding disorders. The company is based in Copenhagen, Denmark. The Danish company was founded in 2019 by Johan Henrik Faber. Benny Sorensen has been the CEO of the company since 2020. | Biotechnology | Chairman Director/Board Member | |
| MINERALYS THERAPEUTICS, INC. | Biotechnology | Director/Board Member Director/Board Member | |
Ocelot Bio, Inc.
 Ocelot Bio, Inc. Pharmaceuticals: MajorHealth Technology Ocelot Bio, Inc. is a clinical-stage biopharmaceutical company that focuses on improving outcomes for patients with end-stage liver disease (ESLD), particularly those suffering from hepatorenal syndrome with acute kidney injury (HRS-AKI) and refractory ascites. The company is based in San Diego, CA. The company is developing therapeutic peptides to treat complications of decompensated cirrhosis, a condition in which the liver is scarred and permanently damaged, leading to liver failure. HRS-AKI is a life-threatening consequence of portal hypertension, which causes a significant drop in arterial pressure and renal perfusion. Ocelot Bio is in early-stage development of OCE-205 for the treatment of ascites, a complication of ESLD-induced portal hypertension that leads to the accumulation of fluid in the peritoneal cavity. The company was founded by Geoffrey Harris, and Katherine Vega Stultz has been the CEO of the company since 2022. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Bioimpact Capital LLC
 Bioimpact Capital LLC Investment ManagersFinance MPM BioImpact LLC (MPM BioImpact) is a venture capital firm a subsidiary of MPM Bioimpact Inc founded in 1996. The firm is headquartered in Cambridge, Massachusetts. | Investment Managers | Private Equity Investor Private Equity Investor | |
Renagade Therapeutics, Inc.
 Renagade Therapeutics, Inc. BiotechnologyHealth Technology Renagade Therapeutics, Inc. is an American US-based company that aims to overcome the limitations of RNA medicines by applying their comprehensive deliver, code, edit, insert technologies to precisely correct disease on an unprecedented scale. The company has developed a broad portfolio of RNA delivery systems, which profoundly expand the array of addressable diseases. The company's proprietary, synergistic toolkit allows them to precisely deliver, code, edit, and insert RNA medicines to treat any disease, anywhere in the body. Renagade is built on a foundation of proprietary delivery technologies to unlock previously inaccessible cells, reprogramming cells with superior expression using the leading RNA coding platform via joint venture with Orna Therapeutics, enabling curative therapies by permanently correcting defective genes with proprietary technology, and industry-leading all-RNA system to enable exon or large gene insertions as a gene therapy 2.0 platform. Renagade is backed by MPM BioImpact and F2 Ventures, leading financial groups who have supported the development of over 50 products to market. | Biotechnology | Founder Director/Board Member |
Statistiques
Internationale
| Etats-Unis | 31 |
| Suisse | 6 |
| Allemagne | 4 |
| Danemark | 3 |
| Belgique | 3 |
Sectorielle
| Health Technology | 30 |
| Finance | 8 |
| Consumer Services | 8 |
| Health Services | 4 |
| Commercial Services | 4 |
Opérationnelle
| Director/Board Member | 438 |
| Corporate Officer/Principal | 154 |
| Independent Dir/Board Member | 107 |
| Chairman | 98 |
| Chief Executive Officer | 74 |
Relations les plus connectées
| Insiders | |
|---|---|
| Ansbert Gadicke | 56 |
| David Hale | 54 |
| Claus Asbjørn Andersson | 41 |
| Jack Nielsen | 38 |
| John Maraganore | 37 |
| Erich Maximilian Platzer | 31 |
| Camille D. Samuels | 30 |
| Gerald Heinz Möller | 29 |
| Luc Dochez | 26 |
| Axel Bolte | 23 |
| Chandra Paul Leo | 22 |
| Andreas Wicki | 21 |
| Emmanuelle Coutanceau | 21 |
| Marten Steen | 21 |
| Ann Rhoads | 19 |
- Bourse
- Insiders
- Priyanka Belawat
- Connexions Sociétés
